ICU Medical Key Executives
This section highlights ICU Medical's key executives, including their titles and compensation details.
Find Contacts at ICU Medical
(Showing 0 of )
ICU Medical Earnings
This section highlights ICU Medical's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-27 | $1.48 | $2.11 |
| Read Transcript | Q3 | 2024 | 2024-11-12 | $1.25 | $1.59 |
| Read Transcript | Q2 | 2024 | 2024-08-07 | $0.98 | $1.56 |
| Read Transcript | Q1 | 2024 | 2024-05-07 | $0.84 | $0.96 |
| Read Transcript | Q4 | 2023 | 2024-02-27 | $1.18 | $1.57 |
| Read Transcript | Q3 | 2023 | 2023-11-06 | $1.29 | $1.57 |
| Read Transcript | Q2 | 2023 | 2023-08-07 | $1.55 | $1.88 |
| Read Transcript | Q1 | 2023 | 2023-05-09 | N/A | N/A |
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
$137.80
Stock Price
$3.38B
Market Cap
15.00K
Employees
San Clemente, CA
Location
Financial Statements
Access annual & quarterly financial statements for ICU Medical, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $2.38B | $2.26B | $2.28B | $1.32B | $1.27B |
| Cost of Revenue | $1.56B | $1.52B | $1.58B | $824.82M | $809.51M |
| Gross Profit | $824.78M | $739.87M | $697.76M | $491.49M | $461.50M |
| Gross Profit Ratio | 34.62% | 32.80% | 30.60% | 37.30% | 36.31% |
| Research and Development Expenses | $88.61M | $85.34M | $92.98M | $47.50M | $42.95M |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $638.76M | $606.69M | $608.35M | $302.58M | $283.95M |
| Other Expenses | $54.44M | $25.01M | $-5.14M | $127.00K | $-975.00K |
| Operating Expenses | $781.82M | $717.05M | $701.33M | $350.21M | $325.93M |
| Cost and Expenses | $2.34B | $2.24B | $2.28B | $1.18B | $1.14B |
| Interest Income | $10.79M | $7.51M | $4.43M | $2.80M | $3.70M |
| Interest Expense | $106.54M | $102.73M | $66.38M | $858.00K | $1.75M |
| Depreciation and Amortization | $- | $228.77M | $258.80M | $99.29M | $94.85M |
| EBITDA | $42.96M | $253.20M | $191.55M | $223.46M | $194.09M |
| EBITDA Ratio | 1.80% | 11.21% | 9.93% | 10.79% | 10.75% |
| Operating Income | $42.96M | $22.82M | $-8.70M | $52.38M | $41.81M |
| Operating Income Ratio | 1.80% | 1.01% | -0.38% | 3.98% | 3.29% |
| Total Other Income Expenses Net | $-108.98M | $-101.12M | $-71.51M | $-59.00K | $-668.00K |
| Income Before Tax | $-66.01M | $-78.30M | $-114.41M | $123.19M | $97.49M |
| Income Before Tax Ratio | -2.77% | -3.47% | -5.02% | 9.36% | 7.67% |
| Income Tax Expense | $51.68M | $-48.64M | $-40.12M | $20.05M | $10.62M |
| Net Income | $-117.69M | $-29.66M | $-74.29M | $103.14M | $86.87M |
| Net Income Ratio | -4.94% | -1.31% | -3.26% | 7.84% | 6.83% |
| EPS | $-4.83 | $-1.23 | $-3.11 | $4.86 | $4.16 |
| EPS Diluted | $-4.83 | $-1.23 | $-3.11 | $4.74 | $4.02 |
| Weighted Average Shares Outstanding | 24.39M | 24.09M | 23.87M | 21.21M | 20.91M |
| Weighted Average Shares Outstanding Diluted | 24.39M | 24.09M | 23.87M | 21.78M | 21.59M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $629.80M | $589.13M | $596.46M | $565.96M | $587.99M | $553.31M | $549.31M | $568.65M | $578.01M | $597.86M | $561.00M | $543.12M | $340.52M | $336.06M | $321.68M | $318.05M | $320.45M | $318.57M | $303.38M | $328.61M |
| Cost of Revenue | $402.55M | $384.28M | $389.03M | $382.69M | $430.19M | $369.39M | $356.98M | $376.61M | $403.07M | $411.46M | $393.41M | $374.30M | $213.03M | $208.27M | $198.15M | $205.37M | $200.58M | $204.64M | $197.09M | $207.19M |
| Gross Profit | $227.26M | $204.85M | $207.43M | $183.26M | $157.80M | $183.92M | $192.33M | $192.04M | $174.94M | $186.40M | $167.59M | $168.83M | $127.49M | $127.79M | $123.53M | $112.68M | $119.87M | $113.92M | $106.28M | $121.42M |
| Gross Profit Ratio | 36.08% | 34.80% | 34.80% | 32.40% | 26.80% | 33.20% | 35.00% | 33.80% | 30.30% | 31.20% | 29.90% | 31.10% | 37.40% | 38.00% | 38.40% | 35.40% | 37.41% | 35.76% | 35.03% | 36.95% |
| Research and Development Expenses | $22.36M | $21.03M | $23.39M | $21.84M | $22.41M | $20.87M | $22.30M | $19.76M | $23.45M | $23.11M | $22.56M | $23.87M | $13.17M | $12.24M | $11.38M | $10.71M | $11.80M | $10.13M | $10.28M | $10.75M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $73.55M | $- | $67.24M | $72.31M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $200.00K | $- | $- | $- |
| Selling General and Administrative Expenses | $158.85M | $162.71M | $159.55M | $157.66M | $154.62M | $148.61M | $150.90M | $152.57M | $142.93M | $153.45M | $158.75M | $153.21M | $81.46M | $74.81M | $73.92M | $72.39M | $73.55M | $70.85M | $67.24M | $72.31M |
| Other Expenses | $8.36M | $12.88M | $16.80M | $-682.00K | $1.66M | $-4.04M | $-1.50M | $-269.00K | $-1.15M | $311.00K | $2.02M | $1.00M | $-122.00K | $-287.00K | $200.00K | $200.00K | $3.26M | $1.25M | $2.05M | $-5.48M |
| Operating Expenses | $189.57M | $196.62M | $199.74M | $179.50M | $177.03M | $169.48M | $173.20M | $172.33M | $166.38M | $176.56M | $181.31M | $177.08M | $94.62M | $87.05M | $85.31M | $83.23M | $85.35M | $79.98M | $77.55M | $83.05M |
| Cost and Expenses | $592.11M | $580.89M | $588.76M | $562.19M | $607.21M | $538.87M | $530.18M | $548.94M | $569.45M | $588.02M | $574.72M | $551.38M | $307.66M | $295.32M | $283.45M | $288.59M | $285.93M | $284.62M | $274.64M | $290.24M |
| Interest Income | $2.73M | $2.60M | $2.81M | $2.65M | $2.30M | $1.75M | $1.71M | $1.75M | $- | $3.34M | $833.00K | $589.00K | $- | $700.00K | $700.00K | $700.00K | $592.00K | $800.00K | $- | $- |
| Interest Expense | $26.19M | $27.29M | $26.65M | $26.42M | $33.05M | $24.18M | $24.12M | $22.52M | $20.07M | $21.15M | $16.27M | $13.64M | $366.00K | $168.00K | $163.00K | $161.00K | $- | $616.00K | $771.00K | $196.00K |
| Depreciation and Amortization | $53.01M | $55.60M | $55.32M | $55.53M | $62.53M | $273.75M | $62.95M | $61.40M | $63.08M | $65.14M | $72.10M | $58.42M | $25.56M | $24.59M | $24.51M | $24.53M | $23.95M | $16.93M | $23.84M | $23.26M |
| EBITDA | $87.42M | $64.96M | $79.81M | $53.14M | $58.89M | $285.49M | $73.55M | $79.66M | $66.90M | $58.48M | $71.52M | $17.27M | $49.27M | $62.71M | $59.53M | $51.78M | $51.87M | $50.58M | $45.45M | $43.84M |
| EBITDA Ratio | 13.88% | 11.03% | 13.38% | 10.48% | 6.45% | 12.43% | 13.68% | 13.22% | 1.28% | 11.51% | 9.93% | 8.45% | 9.62% | 12.04% | 19.81% | 17.25% | 11.79% | 11.05% | 18.01% | 10.01% |
| Operating Income | $37.69M | $8.24M | $7.69M | $3.77M | $-19.23M | $22.85M | $2.76M | $19.44M | $-49.40M | $10.15M | $-48.00K | $-7.25M | $23.82M | $38.38M | $34.47M | $26.57M | $27.02M | $25.53M | $19.56M | $26.06M |
| Operating Income Ratio | 5.98% | 1.40% | 1.29% | 0.67% | -3.27% | 4.13% | 0.50% | 3.42% | -8.55% | 1.70% | -0.01% | -1.34% | 7.00% | 11.42% | 10.72% | 8.35% | 8.43% | 8.01% | 6.45% | 7.93% |
| Total Other Income Expenses Net | $-29.47M | $-26.16M | $-27.23M | $-26.11M | $-24.50M | $-28.22M | $-25.62M | $-22.78M | $-21.23M | $-20.84M | $-16.81M | $-12.64M | $-488.00K | $-455.00K | $362.00K | $522.00K | $3.09M | $636.00K | $1.28M | $-5.68M |
| Income Before Tax | $8.22M | $-17.93M | $-19.53M | $-36.77M | $-36.68M | $-5.37M | $-22.86M | $-13.39M | $-21.45M | $-21.31M | $-16.85M | $-54.80M | $23.34M | $37.92M | $34.83M | $27.09M | $30.11M | $26.17M | $20.84M | $20.38M |
| Income Before Tax Ratio | 1.30% | -3.04% | -3.27% | -6.50% | -6.24% | -0.97% | -4.16% | -2.35% | -3.71% | -3.56% | -3.00% | -10.09% | 6.85% | 11.29% | 10.83% | 8.52% | 9.40% | 8.21% | 6.87% | 6.20% |
| Income Tax Expense | $32.05M | $15.05M | $1.87M | $2.70M | $-19.53M | $-12.60M | $-12.93M | $-3.58M | $-5.91M | $-8.10M | $-9.38M | $-16.73M | $3.41M | $6.84M | $6.43M | $3.36M | $3.97M | $1.18M | $1.93M | $3.55M |
| Net Income | $-23.83M | $-32.98M | $-21.41M | $-39.47M | $-17.15M | $7.24M | $-9.93M | $-9.81M | $-15.54M | $-13.21M | $-7.47M | $-38.07M | $19.93M | $31.08M | $28.40M | $23.73M | $26.14M | $24.99M | $18.91M | $16.83M |
| Net Income Ratio | -3.78% | -5.60% | -3.59% | -6.97% | -2.92% | 1.31% | -1.81% | -1.73% | -2.69% | -2.21% | -1.33% | -7.01% | 5.85% | 9.25% | 8.83% | 7.46% | 8.16% | 7.84% | 6.23% | 5.12% |
| EPS | $-0.97 | $-1.35 | $-0.88 | $-1.63 | $-0.71 | $0.30 | $-0.41 | $-0.41 | $-0.65 | $-0.55 | $-0.31 | $-1.61 | $0.94 | $1.47 | $1.34 | $1.12 | $1.24 | $1.19 | $0.91 | $0.81 |
| EPS Diluted | $-0.97 | $-1.35 | $-0.88 | $-1.63 | $-0.71 | $0.30 | $-0.41 | $-0.41 | $-0.65 | $-0.55 | $-0.31 | $-1.61 | $0.91 | $1.43 | $1.31 | $1.09 | $1.21 | $1.16 | $0.88 | $0.78 |
| Weighted Average Shares Outstanding | 24.49M | 24.44M | 24.39M | 24.22M | 24.14M | 24.13M | 24.07M | 24.01M | 23.99M | 23.91M | 23.90M | 23.64M | 21.26M | 21.21M | 21.20M | 21.15M | 21.02M | 20.95M | 20.88M | 20.78M |
| Weighted Average Shares Outstanding Diluted | 24.49M | 24.44M | 24.39M | 24.22M | 24.14M | 24.37M | 24.07M | 24.01M | 23.99M | 23.91M | 23.90M | 23.65M | 21.81M | 21.73M | 21.70M | 21.70M | 21.61M | 21.56M | 21.51M | 21.51M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $308.57M | $254.22M | $208.78M | $552.83M | $396.10M |
| Short Term Investments | $- | $501.00K | $4.22M | $14.42M | $14.69M |
| Cash and Short Term Investments | $308.57M | $254.72M | $213.01M | $567.25M | $410.78M |
| Net Receivables | $202.70M | $182.15M | $221.72M | $105.89M | $124.09M |
| Inventory | $584.68M | $709.36M | $696.01M | $290.24M | $314.93M |
| Other Current Assets | $346.05M | $75.04M | $101.57M | $71.26M | $85.49M |
| Total Current Assets | $1.44B | $1.22B | $1.24B | $1.03B | $920.78M |
| Property Plant Equipment Net | $496.04M | $685.52M | $710.98M | $508.21M | $513.20M |
| Goodwill | $1.43B | $1.47B | $1.45B | $43.44M | $33.00M |
| Intangible Assets | $740.79M | $870.59M | $982.77M | $188.31M | $197.23M |
| Goodwill and Intangible Assets | $2.17B | $2.34B | $2.43B | $231.75M | $230.23M |
| Long Term Investments | $- | $3.12M | $516.00K | $4.62M | $12.97M |
| Tax Assets | $24.21M | $37.30M | $31.47M | $42.60M | $31.03M |
| Other Non-Current Assets | $68.14M | $88.19M | $105.46M | $63.74M | $55.48M |
| Total Non-Current Assets | $2.76B | $3.16B | $3.28B | $850.93M | $842.91M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $4.20B | $4.38B | $4.52B | $1.88B | $1.76B |
| Account Payables | $148.02M | $150.03M | $215.90M | $81.13M | $71.86M |
| Short Term Debt | $51.00M | $71.16M | $48.67M | $9.65M | $9.29M |
| Tax Payables | $11.24M | $14.46M | $6.20M | $1.45M | $303.00K |
| Deferred Revenue | $- | $31.64M | $30.84M | $12.65M | $5.57M |
| Other Current Liabilities | $345.92M | $214.54M | $192.95M | $96.54M | $109.02M |
| Total Current Liabilities | $556.18M | $481.84M | $494.56M | $200.78M | $195.49M |
| Long Term Debt | $1.53B | $1.63B | $1.69B | $36.04M | $43.41M |
| Deferred Revenue Non-Current | $- | $10.59M | $16.24M | $202.00K | $1.20M |
| Deferred Tax Liabilities Non-Current | $48.81M | $55.87M | $126.01M | $1.49M | $1.66M |
| Other Non-Current Liabilities | $101.84M | $74.04M | $102.46M | $26.40M | $19.67M |
| Total Non-Current Liabilities | $1.68B | $1.77B | $1.93B | $63.93M | $65.94M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $2.24B | $2.26B | $2.43B | $264.71M | $261.43M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $2.45M | $2.41M | $2.40M | $2.13M | $2.11M |
| Retained Earnings | $690.16M | $807.85M | $837.50M | $911.79M | $808.65M |
| Accumulated Other Comprehensive Income Loss | $-139.40M | $-53.08M | $-80.98M | $-19.27M | $-1.52M |
| Other Total Stockholders Equity | $1.41B | $1.37B | $1.33B | $721.38M | $693.03M |
| Total Stockholders Equity | $1.97B | $2.12B | $2.09B | $1.62B | $1.50B |
| Total Equity | $1.97B | $2.12B | $2.09B | $1.62B | $1.50B |
| Total Liabilities and Stockholders Equity | $4.20B | $4.38B | $4.52B | $1.88B | $1.76B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $4.20B | $4.38B | $4.52B | $1.88B | $1.76B |
| Total Investments | $3.04M | $3.62M | $7.92M | $19.04M | $27.66M |
| Total Debt | $1.58B | $1.70B | $1.65B | $45.05M | $52.15M |
| Net Debt | $1.27B | $1.45B | $1.44B | $-507.78M | $-343.95M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $308.57M | $312.51M | $302.65M | $251.42M | $254.22M | $197.19M | $195.89M | $220.95M | $208.78M | $243.88M | $255.70M | $329.43M | $552.83M | $519.49M | $462.04M | $424.25M | $396.10M | $350.99M | $446.13M | $419.56M |
| Short Term Investments | $- | $- | $302.65M | $1.19M | $501.00K | $1.81M | $1.81M | $3.23M | $4.22M | $2.92M | $13.19M | $14.86M | $14.42M | $18.01M | $14.66M | $11.69M | $14.69M | $12.54M | $14.56M | $20.11M |
| Cash and Short Term Investments | $308.57M | $312.51M | $302.65M | $251.42M | $254.72M | $199.00M | $197.70M | $224.18M | $213.01M | $246.80M | $268.89M | $344.29M | $567.25M | $537.49M | $476.70M | $435.94M | $410.78M | $363.54M | $460.70M | $439.67M |
| Net Receivables | $202.70M | $198.78M | $154.94M | $169.00M | $182.15M | $161.80M | $162.22M | $139.46M | $221.72M | $240.96M | $246.65M | $236.53M | $105.89M | $116.04M | $142.01M | $140.12M | $124.09M | $164.54M | $217.98M | $198.16M |
| Inventory | $584.68M | $692.04M | $682.87M | $693.01M | $709.36M | $759.62M | $775.27M | $747.97M | $696.01M | $625.27M | $583.05M | $536.31M | $290.24M | $291.60M | $299.61M | $300.09M | $314.93M | $321.96M | $322.77M | $311.60M |
| Other Current Assets | $346.05M | $54.73M | $68.97M | $74.30M | $75.04M | $98.23M | $111.70M | $106.79M | $101.57M | $86.34M | $91.25M | $56.86M | $71.26M | $80.31M | $55.04M | $52.03M | $85.49M | $48.77M | $35.26M | $55.47M |
| Total Current Assets | $1.44B | $1.26B | $1.24B | $1.19B | $1.22B | $1.22B | $1.24B | $1.21B | $1.24B | $1.20B | $1.19B | $1.17B | $1.03B | $1.01B | $973.35M | $928.18M | $920.78M | $900.14M | $1.04B | $1.00B |
| Property Plant Equipment Net | $496.04M | $655.38M | $663.77M | $670.12M | $682.82M | $682.53M | $692.57M | $703.85M | $710.98M | $735.15M | $753.44M | $768.98M | $508.21M | $499.02M | $502.10M | $504.33M | $513.20M | $504.15M | $504.54M | $506.05M |
| Goodwill | $1.43B | $1.48B | $1.45B | $1.46B | $1.47B | $1.44B | $1.46B | $1.46B | $1.45B | $1.37B | $1.42B | $1.53B | $43.44M | $32.76M | $32.93M | $32.95M | $33.00M | $32.65M | $32.47M | $30.77M |
| Intangible Assets | $740.79M | $785.82M | $805.79M | $836.90M | $870.59M | $891.28M | $929.83M | $957.68M | $982.77M | $1.02B | $1.08B | $1.09B | $188.31M | $192.78M | $189.62M | $193.07M | $197.23M | $200.43M | $203.72M | $206.84M |
| Goodwill and Intangible Assets | $2.17B | $2.26B | $2.26B | $2.30B | $2.34B | $2.34B | $2.39B | $2.42B | $2.43B | $2.39B | $2.50B | $2.62B | $231.75M | $225.54M | $222.55M | $226.03M | $230.23M | $233.08M | $236.19M | $237.60M |
| Long Term Investments | $- | $- | $38.37M | $3.10M | $39.30M | $3.15M | $3.16M | $3.17M | $516.00K | $5.02M | $5.04M | $5.75M | $4.62M | $7.17M | $15.67M | $18.83M | $12.97M | $- | $- | $- |
| Tax Assets | $24.21M | $40.65M | $38.86M | $40.20M | $37.30M | $31.47M | $31.47M | $31.47M | $31.47M | $15.48M | $43.94M | $77.57M | $42.60M | $35.59M | $31.12M | $29.11M | $31.03M | $36.37M | $28.78M | $21.90M |
| Other Non-Current Assets | $68.14M | $86.84M | $52.95M | $90.97M | $56.39M | $104.58M | $96.80M | $98.72M | $105.46M | $105.09M | $96.19M | $98.86M | $63.74M | $60.80M | $58.05M | $58.74M | $55.48M | $55.80M | $52.85M | $49.24M |
| Total Non-Current Assets | $2.76B | $3.05B | $3.05B | $3.10B | $3.16B | $3.16B | $3.22B | $3.26B | $3.28B | $3.25B | $3.40B | $3.57B | $850.93M | $828.11M | $829.49M | $837.05M | $842.91M | $829.40M | $822.36M | $814.80M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $4.20B | $4.31B | $4.29B | $4.29B | $4.38B | $4.38B | $4.46B | $4.47B | $4.52B | $4.45B | $4.59B | $4.75B | $1.88B | $1.84B | $1.80B | $1.77B | $1.76B | $1.73B | $1.86B | $1.82B |
| Account Payables | $148.02M | $168.56M | $155.51M | $152.48M | $150.03M | $149.29M | $167.05M | $186.42M | $215.90M | $205.04M | $201.87M | $200.99M | $81.13M | $62.01M | $69.78M | $73.05M | $71.86M | $81.03M | $101.13M | $86.35M |
| Short Term Debt | $51.00M | $51.00M | $69.91M | $70.35M | $72.02M | $66.44M | $59.56M | $56.12M | $48.67M | $43.01M | $39.64M | $35.27M | $9.65M | $9.29M | $9.47M | $9.46M | $9.29M | $8.93M | $158.25M | $157.54M |
| Tax Payables | $11.24M | $5.79M | $4.14M | $11.18M | $14.46M | $11.44M | $19.95M | $5.53M | $6.20M | $25.94M | $26.95M | $26.64M | $1.45M | $2.64M | $6.74M | $4.82M | $303.00K | $935.00K | $7.36M | $944.00K |
| Deferred Revenue | $- | $- | $33.79M | $32.75M | $31.64M | $28.77M | $27.69M | $30.99M | $30.84M | $31.18M | $35.01M | $40.87M | $12.65M | $5.54M | $5.36M | $8.20M | $5.57M | $8.43M | $13.52M | $9.78M |
| Other Current Liabilities | $345.92M | $324.21M | $248.55M | $188.60M | $213.69M | $208.11M | $209.62M | $183.12M | $192.95M | $183.86M | $182.51M | $190.35M | $96.54M | $106.22M | $92.94M | $84.93M | $109.02M | $86.52M | $78.90M | $102.69M |
| Total Current Liabilities | $556.18M | $549.56M | $511.91M | $455.36M | $481.84M | $464.04M | $483.88M | $462.18M | $494.56M | $489.03M | $485.99M | $494.12M | $200.78M | $185.08M | $183.66M | $179.86M | $195.49M | $185.36M | $359.15M | $357.30M |
| Long Term Debt | $1.53B | $1.54B | $1.61B | $1.62B | $1.63B | $1.65B | $1.66B | $1.61B | $1.69B | $1.69B | $1.71B | $1.72B | $36.04M | $37.60M | $39.92M | $41.92M | $43.41M | $44.79M | $46.58M | $45.77M |
| Deferred Revenue Non-Current | $- | $- | $10.02M | $10.61M | $10.59M | $11.84M | $15.36M | $16.59M | $16.24M | $21.98M | $23.36M | $23.00M | $202.00K | $236.00K | $270.00K | $996.00K | $1.20M | $371.00K | $404.00K | $620.00K |
| Deferred Tax Liabilities Non-Current | $48.81M | $48.54M | $53.79M | $55.59M | $55.87M | $77.84M | $89.68M | $114.59M | $126.01M | $153.60M | $204.99M | $220.63M | $1.49M | $1.66M | $1.66M | $1.66M | $1.66M | $2.09M | $2.09M | $1.99M |
| Other Non-Current Liabilities | $101.84M | $115.01M | $63.74M | $81.31M | $74.04M | $76.25M | $96.58M | $181.27M | $102.46M | $78.62M | $83.53M | $112.61M | $26.20M | $24.80M | $20.06M | $20.02M | $19.67M | $44.71M | $39.04M | $35.41M |
| Total Non-Current Liabilities | $1.68B | $1.71B | $1.74B | $1.77B | $1.77B | $1.81B | $1.86B | $1.91B | $1.93B | $1.95B | $2.02B | $2.07B | $63.93M | $64.30M | $61.91M | $64.60M | $65.94M | $91.96M | $88.11M | $83.78M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $2.24B | $2.26B | $2.25B | $2.22B | $2.26B | $2.28B | $2.35B | $2.37B | $2.43B | $2.44B | $2.50B | $2.57B | $264.71M | $249.38M | $245.58M | $244.46M | $261.43M | $277.32M | $447.26M | $441.09M |
| Preferred Stock | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $2.45M | $2.45M | $2.44M | $2.44M | $2.41M | $2.41M | $2.41M | $2.41M | $2.40M | $2.40M | $2.39M | $2.39M | $2.13M | $2.12M | $2.12M | $2.12M | $2.11M | $2.10M | $2.09M | $2.08M |
| Retained Earnings | $690.16M | $713.99M | $746.97M | $768.38M | $807.85M | $824.99M | $817.75M | $827.69M | $837.50M | $853.04M | $866.25M | $873.72M | $911.79M | $891.86M | $860.78M | $832.38M | $808.65M | $782.51M | $757.52M | $738.62M |
| Accumulated Other Comprehensive Income Loss | $-139.40M | $-62.44M | $-91.78M | $-69.54M | $-53.08M | $-84.73M | $-48.79M | $-61.60M | $-80.98M | $-165.68M | $-92.28M | $-628.00K | $-19.27M | $-15.12M | $-8.95M | $-9.91M | $-1.52M | $-15.53M | $-23.18M | $-28.91M |
| Other Total Stockholders Equity | $1.41B | $1.39B | $1.38B | $1.37B | $1.37B | $1.36B | $1.34B | $1.33B | $1.33B | $1.32B | $1.31B | $1.30B | $721.38M | $711.10M | $703.31M | $696.18M | $693.03M | $683.15M | $675.36M | $664.11M |
| Total Stockholders Equity | $1.97B | $2.05B | $2.04B | $2.07B | $2.12B | $2.10B | $2.11B | $2.10B | $2.09B | $2.01B | $2.09B | $2.18B | $1.62B | $1.59B | $1.56B | $1.52B | $1.50B | $1.45B | $1.41B | $1.38B |
| Total Equity | $1.97B | $2.05B | $2.04B | $2.07B | $2.12B | $2.10B | $2.11B | $2.10B | $2.09B | $2.01B | $2.09B | $2.18B | $1.62B | $1.59B | $1.56B | $1.52B | $1.50B | $1.45B | $1.41B | $1.38B |
| Total Liabilities and Stockholders Equity | $4.20B | $4.31B | $4.29B | $4.29B | $4.38B | $4.38B | $4.46B | $4.47B | $4.52B | $4.45B | $4.59B | $4.75B | $1.88B | $1.84B | $1.80B | $1.77B | $1.76B | $1.73B | $1.86B | $1.82B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $4.20B | $4.31B | $4.29B | $4.29B | $4.38B | $4.38B | $4.46B | $4.47B | $4.52B | $4.45B | $4.59B | $4.75B | $1.88B | $1.84B | $1.80B | $1.77B | $1.76B | $1.73B | $1.86B | $1.82B |
| Total Investments | $3.04M | $3.08M | $38.37M | $14.62M | $39.80M | $1.81M | $1.81M | $3.23M | $7.92M | $7.94M | $43.36M | $20.61M | $19.04M | $28.43M | $30.33M | $30.53M | $27.66M | $12.54M | $14.56M | $20.11M |
| Total Debt | $1.58B | $1.59B | $1.68B | $1.69B | $1.70B | $1.63B | $1.64B | $1.65B | $1.65B | $1.74B | $1.75B | $1.75B | $45.05M | $46.27M | $48.77M | $50.79M | $52.15M | $53.24M | $204.82M | $150.00M |
| Net Debt | $1.27B | $1.28B | $1.38B | $1.44B | $1.45B | $1.44B | $1.45B | $1.43B | $1.44B | $1.49B | $1.49B | $1.42B | $-507.78M | $-473.22M | $-413.27M | $-373.46M | $-343.95M | $-297.75M | $-241.31M | $-269.56M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-117.69M | $-29.66M | $-74.29M | $103.14M | $86.87M |
| Depreciation and Amortization | $219.51M | $228.79M | $235.15M | $89.70M | $94.85M |
| Deferred Income Tax | $- | $- | $- | $2.83M | $3.77M |
| Stock Based Compensation | $46.88M | $40.56M | $36.02M | $27.34M | $23.95M |
| Change in Working Capital | $- | $-135.60M | $-303.73M | $15.04M | $-16.97M |
| Accounts Receivables | $-46.84M | $48.63M | $-19.15M | $13.76M | $78.05M |
| Inventory | $16.83M | $-6.08M | $-201.09M | $20.82M | $19.20M |
| Accounts Payables | $12.53M | $-68.30M | $37.47M | $2.35M | $-46.41M |
| Other Working Capital | $- | $-109.86M | $-120.95M | $-21.88M | $-67.80M |
| Other Non Cash Items | $55.33M | $62.10M | $44.71M | $29.50M | $30.27M |
| Net Cash Provided by Operating Activities | $204.03M | $166.20M | $-62.13M | $267.54M | $222.75M |
| Investments in Property Plant and Equipment | $-79.37M | $-83.89M | $-99.33M | $-81.17M | $-100.39M |
| Acquisitions Net | $- | $- | $-1.84B | $-14.45M | $-8.38M |
| Purchases of Investments | $- | $- | $-3.40M | $-13.28M | $-32.83M |
| Sales Maturities of Investments | $500.00K | $4.22M | $36.43M | $18.00M | $28.90M |
| Other Investing Activities | $-10.09M | $-8.28M | $989.00K | $218.00K | $14.56M |
| Net Cash Used for Investing Activities | $-88.96M | $-87.95M | $-1.91B | $-90.69M | $-98.14M |
| Debt Repayment | $-52.15M | $-30.65M | $1.64B | $-607.00K | $-357.00K |
| Common Stock Issued | $- | $- | $8.79M | $9.37M | $13.19M |
| Common Stock Repurchased | $- | $-9.35M | $-10.88M | $-8.34M | $-12.88M |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-3.65M | $- | $6.61M | $-16.26M | $317.00K |
| Net Cash Used Provided by Financing Activities | $-55.80M | $-35.98M | $1.64B | $-16.87M | $-40.00K |
| Effect of Forex Changes on Cash | $-4.93M | $3.16M | $-9.48M | $-3.25M | $2.85M |
| Net Change in Cash | $54.34M | $45.44M | $-344.04M | $156.73M | $127.43M |
| Cash at End of Period | $308.57M | $254.22M | $208.78M | $552.83M | $396.10M |
| Cash at Beginning of Period | $254.22M | $208.78M | $552.83M | $396.10M | $268.67M |
| Operating Cash Flow | $204.03M | $166.20M | $-62.13M | $267.54M | $222.75M |
| Capital Expenditure | $-79.37M | $-93.67M | $-99.33M | $-81.17M | $-100.39M |
| Free Cash Flow | $124.66M | $72.53M | $-161.46M | $186.37M | $122.36M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-23.83M | $-32.98M | $-21.41M | $-39.47M | $-17.15M | $7.24M | $-9.93M | $-9.81M | $-15.54M | $-13.21M | $-7.47M | $-38.07M | $19.93M | $31.08M | $28.40M | $23.73M | $26.14M | $24.99M | $18.91M | $16.83M |
| Depreciation and Amortization | $53.01M | $55.67M | $55.32M | $55.53M | $57.16M | $58.37M | $57.50M | $55.74M | $56.81M | $58.64M | $66.56M | $53.14M | $23.13M | $17.46M | $24.57M | $24.53M | $23.95M | $23.79M | $23.84M | $23.26M |
| Deferred Income Tax | $- | $- | $- | $- | $-19.53M | $-12.60M | $3.50M | $- | $16.73M | $- | $- | $-16.73M | $874.00K | $1.35M | $-42.00K | $868.00K | $-17.29M | $3.14M | $273.00K | $-254.00K |
| Stock Based Compensation | $12.52M | $11.77M | $11.00M | $11.60M | $10.69M | $10.95M | $9.77M | $9.16M | $7.43M | $8.74M | $7.76M | $12.09M | $8.11M | $6.53M | $6.68M | $6.02M | $5.34M | $6.26M | $5.41M | $6.94M |
| Change in Working Capital | $-17.67M | $-13.49M | $24.49M | $4.10M | $14.06M | $-37.71M | $-82.11M | $-29.84M | $-69.71M | $-63.13M | $-119.60M | $-51.28M | $25.32M | $5.83M | $-10.51M | $-5.61M | $13.09M | $8.63M | $-22.92M | $-15.77M |
| Accounts Receivables | $-35.33M | $-18.23M | $- | $13.97M | $5.55M | $-3.71M | $-35.23M | $82.03M | $-10.20M | $-7.87M | $-23.58M | $22.49M | $9.95M | $1.73M | $572.00K | $1.51M | $39.12M | $33.64M | $4.39M | $899.00K |
| Inventory | $7.41M | $-11.68M | $6.93M | $14.16M | $60.58M | $9.38M | $-26.67M | $-49.37M | $-49.26M | $-51.82M | $-63.85M | $-36.17M | $4.30M | $3.14M | $160.00K | $13.21M | $10.34M | $378.00K | $-10.89M | $19.37M |
| Accounts Payables | $-8.55M | $11.65M | $4.12M | $5.31M | $-3.25M | $-18.18M | $-19.34M | $-27.52M | $7.06M | $8.26M | $2.65M | $19.50M | $12.72M | $-8.73M | $-4.06M | $2.41M | $-8.38M | $-14.73M | $11.76M | $-35.06M |
| Other Working Capital | $18.80M | $4.77M | $13.44M | $-29.34M | $-48.82M | $-25.20M | $-873.00K | $-34.97M | $-17.32M | $-11.72M | $-19.70M | $-57.10M | $-1.65M | $9.68M | $-7.18M | $-22.73M | $-27.98M | $-10.66M | $-28.18M | $-978.00K |
| Other Non Cash Items | $16.16M | $15.12M | $12.56M | $103.24M | $46.05M | $8.92M | $19.80M | $15.99M | $2.56M | $11.27M | $-9.51M | $39.51M | $5.26M | $16.58M | $5.66M | $1.78M | $27.30M | $8.67M | $3.71M | $8.51M |
| Net Cash Provided by Operating Activities | $40.19M | $36.10M | $81.95M | $45.79M | $91.27M | $35.16M | $-1.47M | $41.24M | $-1.71M | $2.31M | $-61.38M | $-1.34M | $82.62M | $78.83M | $54.76M | $51.32M | $78.53M | $75.49M | $29.22M | $39.52M |
| Investments in Property Plant and Equipment | $-24.08M | $-14.55M | $-21.88M | $-18.87M | $-31.97M | $-24.56M | $-20.40M | $-16.74M | $-24.05M | $-22.80M | $-26.49M | $-25.99M | $-24.49M | $-22.85M | $-17.93M | $-15.90M | $-31.70M | $-26.07M | $-15.20M | $-27.42M |
| Acquisitions Net | $- | $-692.00K | $- | $507.00K | $20.00K | $50.00K | $1.38M | $54.00K | $56.00K | $33.00K | $- | $-1.84B | $-14.45M | $-6.08M | $148.00K | $-1.87M | $-2.06M | $-2.22M | $- | $-1.96M |
| Purchases of Investments | $- | $- | $- | $- | $1.43M | $- | $-1.38M | $-54.00K | $- | $-33.00K | $-1.40M | $-1.99M | $3.25M | $-3.25M | $- | $-10.03M | $-23.22M | $-2.52M | $- | $-7.08M |
| Sales Maturities of Investments | $- | $- | $- | $500.00K | $1.30M | $- | $1.42M | $1.50M | $- | $10.23M | $22.70M | $3.50M | $6.00M | $5.00M | $- | $7.00M | $8.00M | $4.50M | $5.50M | $10.90M |
| Other Investing Activities | $-2.46M | $-7.62M | $185.00K | $507.00K | $-1.43M | $50.00K | $1.38M | $54.00K | $56.00K | $33.00K | $19.24M | $900.00K | $-3.25M | $6.09M | $148.00K | $1.93M | $8.08M | $2.23M | $16.00K | $2.09M |
| Net Cash Used for Investing Activities | $-26.55M | $-22.86M | $-21.69M | $-17.86M | $-30.65M | $-24.51M | $-17.61M | $-15.18M | $-24.00M | $-12.53M | $-5.19M | $-1.87B | $-32.94M | $-21.09M | $-17.78M | $-18.88M | $-40.90M | $-24.08M | $-9.68M | $-23.47M |
| Debt Repayment | $-13.12M | $-10.41M | $-13.02M | $-12.99M | $-7.72M | $-7.68M | $-7.67M | $-7.58M | $-10.60M | $-2.28M | $-2.35M | $1.66B | $-159.00K | $-152.00K | $-155.00K | $-141.00K | $-126.00K | $-150.12M | $- | $150.00M |
| Common Stock Issued | $- | $-3.07M | $- | $150.00K | $-4.02M | $1.79M | $2.06M | $171.00K | $8.79M | $4.91M | $18.00K | $2.97M | $9.37M | $1.55M | $552.00K | $4.86M | $13.19M | $- | $- | $- |
| Common Stock Repurchased | $- | $11.69M | $- | $-11.40M | $-129.00K | $-503.00K | $-293.00K | $-8.43M | $-10.88M | $-103.00K | $-1.70M | $-8.74M | $-8.34M | $-290.00K | $-96.00K | $-7.72M | $-55.00K | $-260.00K | $-387.00K | $-12.17M |
| Dividends Paid | $- | $- | $- | $- | $-11.48M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $4.93M | $27.00K | $2.64M | $-13.85M | $-129.00K | $1.29M | $1.77M | $-8.25M | $212.00K | $4.81M | $-1.68M | $1.12M | $-15.12M | $1.26M | $456.00K | $-2.86M | $4.55M | $1.53M | $6.12M | $560.00K |
| Net Cash Used Provided by Financing Activities | $-8.19M | $-10.38M | $-10.38M | $-26.84M | $-7.85M | $-6.40M | $-5.90M | $-15.84M | $-10.38M | $2.53M | $-4.03M | $1.65B | $-15.28M | $1.11M | $301.00K | $-3.00M | $4.43M | $-148.59M | $5.74M | $138.39M |
| Effect of Forex Changes on Cash | $-9.40M | $7.01M | $1.35M | $-3.88M | $4.26M | $-2.95M | $-83.00K | $1.94M | $999.00K | $-4.13M | $-3.12M | $-3.22M | $-1.06M | $-1.41M | $504.00K | $-1.29M | $3.06M | $2.04M | $1.30M | $-3.55M |
| Net Change in Cash | $-3.95M | $9.86M | $51.23M | $-2.80M | $57.03M | $1.30M | $-25.06M | $12.16M | $-35.09M | $-11.82M | $-73.73M | $-223.40M | $33.34M | $57.45M | $37.79M | $28.15M | $45.10M | $-95.14M | $26.58M | $150.89M |
| Cash at End of Period | $308.57M | $312.51M | $302.65M | $251.42M | $254.22M | $197.19M | $195.89M | $220.95M | $208.78M | $243.88M | $255.70M | $329.43M | $552.83M | $519.49M | $462.04M | $424.25M | $396.10M | $350.99M | $446.13M | $419.56M |
| Cash at Beginning of Period | $312.51M | $302.65M | $251.42M | $254.22M | $197.19M | $195.89M | $220.95M | $208.78M | $243.88M | $255.70M | $329.43M | $552.83M | $519.49M | $462.04M | $424.25M | $396.10M | $350.99M | $446.13M | $419.56M | $268.67M |
| Operating Cash Flow | $40.19M | $36.10M | $81.95M | $45.79M | $91.27M | $35.16M | $-1.47M | $41.24M | $-1.71M | $2.31M | $-61.38M | $-1.34M | $82.62M | $78.83M | $54.76M | $51.32M | $78.53M | $75.49M | $29.22M | $39.52M |
| Capital Expenditure | $-26.60M | $-14.55M | $-21.88M | $-18.87M | $-31.97M | $-24.56M | $-20.40M | $-16.74M | $-24.05M | $-22.80M | $-26.49M | $-25.99M | $-24.49M | $-22.85M | $-17.93M | $-15.90M | $-31.70M | $-26.07M | $-15.20M | $-27.42M |
| Free Cash Flow | $13.60M | $21.55M | $60.08M | $26.92M | $59.30M | $10.60M | $-21.88M | $24.51M | $-25.77M | $-20.49M | $-87.87M | $-27.34M | $58.13M | $55.98M | $36.84M | $35.42M | $46.82M | $49.42M | $14.02M | $12.10M |
ICU Medical Dividends
Explore ICU Medical's dividend history, including dividend yield, payout ratio, and historical payments.
ICU Medical News
Read the latest news about ICU Medical, including recent articles, headlines, and updates.
ICU Medical to Present at the 24th Annual Needham Virtual Healthcare Conference
SAN CLEMENTE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the 24th Annual Needham Virtual Healthcare Conference being held April 7-10, 2025. ICU Medical's presentation will be on Monday, April 7, 2025 at 8:00 a.m. PT (11:00 a.m. ET). Company management will also be participating in one-on-one meetings on Monday, April 7, 2025.
ICU Medical to Participate at the KeyBanc Healthcare Forum
SAN CLEMENTE, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will participate in a fireside chat at the KeyBanc Healthcare Forum being held virtually, March 18-19, 2025. ICU Medical's fireside chat will be on Wednesday, March 19, 2025 at 8:15 a.m. PT (11:15 a.m. ET). Company management will also be participating in one-on-one meetings on Wednesday, March 19, 2025.
ICU Medical, Inc. (ICUI) Q4 2024 Earnings Call Transcript
ICU Medical, Inc. (NASDAQ:ICUI ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants John Mills - ICR, IR Vivek Jain - Chairman and CEO Brian Bonnell - Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James Brett Fishbin - KeyBanc Capital Markets Charlie Strauzer - CJS Securities Michael Toomey - Jefferies Joseph Conway - Needham Operator Good day. And welcome to the ICU Medical, Inc. Fourth Quarter 2024 Earnings Conference Call.
ICU Medical Announces Fourth Quarter 2024 Results and Provides Fiscal Year 2025 Guidance
SAN CLEMENTE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended December 31, 2024.
ICU Medical Announces Time of Fourth Quarter 2024 Earnings Conference Call
SAN CLEMENTE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its fourth quarter 2024 earnings release and conference call.
ICU Medical to Present at the Raymond James 46th Annual Institutional Investors Conference
SAN CLEMENTE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the Raymond James 46th Annual Institutional Investors Conference being held in Orlando, Florida, March 3-5, 2025. ICU Medical's presentation will be on Monday, March 3, 2025 at 5:40 a.m. PT (8:40 a.m. ET). Company management will also be participating in one-on-one meetings on Monday, March 3, 2025.
ICU Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN CLEMENTE, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, California, January 13-16, 2025. ICU Medical's presentation will be on Wednesday, January 15, 2025 at 10:30 a.m. PT (1:30 p.m. ET). Company management will also be participating in one-on-one meetings on Wednesday, January 15, 2025 and Thursday, January 16, 2025.
ICU Medical Inc. (ICUI) Q3 2024 Earnings Call Transcript
ICU Medical Inc. (NASDAQ:ICUI ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants John Mills - ICR Vivek Jain - Chief Executive Officer and Chairman Brian Bonnell - Chief Financial Officer Conference Call Participants Brett Fishbin - KeyBanc Eric Fleming - Raymond James Larry Solow - CJS Securities Kristen Stewart - CL King Mike Matson - Needham and Company Michael Toomey - Jefferies Operator Good day, everyone, and welcome to today's ICU Medical Inc.'s Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc., a Subsidiary of Otsuka Holdings Co. Ltd., Announce Creation of a Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America
The partnership creates one of the largest global IV solutions manufacturing networks with combined production of an estimated 1.4 billion annual units and aims to bring additional supply chain resiliency and new innovation to the North American IV solutions market. Joint venture becomes part of a global manufacturing network with scale and redundancy Intends to add long-term supply resiliency and accelerate IV solutions new product development in North America Combines Otsuka Pharmaceutical Factory, Inc.'s expertise and global manufacturing scale with ICU Medical's strong North American production and distribution ICU Medical to provide commercial services to the joint venture Expected to become operationally effective in early Q2 2025 Full presentation available for view here SAN CLEMENTE, Calif.
ICU Medical to Participate at the UBS Global Healthcare Conference
SAN CLEMENTE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the UBS Global Healthcare Conference being held in Rancho Palos Verdes, California, November 11-14, 2024. ICU Medical's presentation will be on Wednesday, November 13, 2024 at 4:15 p.m. PT (7:15 p.m. ET). Company management will also be participating in one-on-one meetings on Wednesday, November 13, 2024.
ICU Medical Announces Time of Third Quarter 2024 Earnings Conference Call
SAN CLEMENTE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2024 earnings release and conference call.
Is ICU Medical (ICUI) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ICU Medical to Participate in Upcoming Investor Conferences
SAN CLEMENTE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the following investor conferences in September:
ICU Medical Inc (ICUI) Q2 2024 Earnings Call Transcript
ICU Medical Inc (NASDAQ:ICUI ) Q2 2024 Results Conference Call August 7, 2024 4:30 PM ET Company Participants John Mills - Managing Partner Vivek Jain - CEO & Chairman of the Board Brian Bonnell - CFO & Treasurer Conference Call Participants Larry Solow - CJS Securities Kristen Stewart - CL King Brett Fishbin - KeyBanc Capital Markets Mike Matson - Needham & Company Jayson Bedford - Raymond James Operator Good afternoon, ladies and gentlemen, and welcome to the ICU Medical Inc Second Quarter 2024 Earnings Conference Call. At this time, all lines are in a listen-only mode.
Swiss National Bank Lowers Stock Position in ICU Medical, Inc. (NASDAQ:ICUI)
Swiss National Bank decreased its holdings in ICU Medical, Inc. (NASDAQ:ICUI – Free Report) by 10.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,419 shares of the medical instruments supplier’s stock after selling 4,600 shares during the quarter. Swiss National Bank owned about 0.17% of ICU Medical worth $4,031,000 at the end of the most recent quarter. A number of other large investors have also recently bought and sold shares of ICUI. WCM Investment Management LLC boosted its stake in shares of ICU Medical by 37.5% during the fourth quarter. WCM Investment Management LLC now owns 242,808 shares of the medical instruments supplier’s stock worth $24,223,000 after buying an additional 66,221 shares during the period. State of Alaska Department of Revenue grew its stake in shares of ICU Medical by 417.8% in the 4th quarter. State of Alaska Department of Revenue now owns 12,475 shares of the medical instruments supplier’s stock valued at $1,244,000 after purchasing an additional 10,066 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of ICU Medical by 7.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 168,957 shares of the medical instruments supplier’s stock valued at $20,108,000 after purchasing an additional 11,364 shares during the period. Louisiana State Employees Retirement System acquired a new position in shares of ICU Medical in the fourth quarter valued at approximately $1,007,000. Finally, Federated Hermes Inc. raised its stake in shares of ICU Medical by 6.5% during the third quarter. Federated Hermes Inc. now owns 125,967 shares of the medical instruments supplier’s stock worth $14,991,000 after purchasing an additional 7,675 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock. Wall Street Analyst Weigh In Separately, KeyCorp boosted their price objective on shares of ICU Medical from $134.00 to $136.00 and gave the company an “overweight” rating in a research note on Wednesday, February 28th. Check Out Our Latest Report on ICU Medical Insider Activity at ICU Medical In other ICU Medical news, Director Elisha W. Finney sold 300 shares of the company’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $104.95, for a total transaction of $31,485.00. Following the transaction, the director now directly owns 2,129 shares in the company, valued at $223,438.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other ICU Medical news, COO Christian B. Voigtlander sold 13,603 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $107.19, for a total transaction of $1,458,105.57. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Elisha W. Finney sold 300 shares of the firm’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $104.95, for a total value of $31,485.00. Following the completion of the transaction, the director now owns 2,129 shares of the company’s stock, valued at approximately $223,438.55. The disclosure for this sale can be found here. Insiders sold 26,562 shares of company stock worth $2,788,117 over the last 90 days. Company insiders own 6.70% of the company’s stock. ICU Medical Stock Performance NASDAQ ICUI opened at $103.99 on Monday. The stock has a market capitalization of $2.53 billion, a price-to-earnings ratio of -42.44 and a beta of 0.72. The business’s 50 day moving average is $100.63 and its two-hundred day moving average is $97.29. ICU Medical, Inc. has a 12-month low of $78.28 and a 12-month high of $196.57. The company has a current ratio of 2.61, a quick ratio of 1.09 and a debt-to-equity ratio of 0.76. ICU Medical (NASDAQ:ICUI – Get Free Report) last announced its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.39. ICU Medical had a positive return on equity of 5.38% and a negative net margin of 2.63%. The firm had revenue of $587.86 million for the quarter, compared to analyst estimates of $564.77 million. Research analysts expect that ICU Medical, Inc. will post 3.53 EPS for the current year. ICU Medical Company Profile (Free Report) ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
ICU Medical, Inc. (ICUI) Q1 2024 Earnings Call Transcript
ICU Medical, Inc. (NASDAQ:ICUI ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants John Mills - Managing Partner at ICR Vivek Jain - Chief Executive Officer & Chairman Brian Bonnell - Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James Brett Fishbin - KeyBanc Kristen Stewart - CL King Larry Solow - CJS Securities Operator Good afternoon, ladies and gentlemen and welcome to the ICU Medical Incorporated. First Quarter 2024 Earnings Conference Call.
ICU Medical Announces Time of First Quarter 2024 Earnings Conference Call
SAN CLEMENTE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2024 earnings release and conference call.
ICU Medical to Present at the KeyBanc Life Sciences & MedTech Investor Forum
SAN CLEMENTE, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the KeyBanc Life Sciences & MedTech Investor Forum being held virtually March 19-20, 2024. ICU Medical's presentation will be on Wednesday, March 20, 2024 at 11:15 a.m. PT (2:15 p.m. ET). Company management will also be participating in one-on-one meetings on Wednesday, March 20, 2024.
ICU Medical to Present at the Raymond James 45ᵗʰ Annual Institutional Investors Conference
SAN CLEMENTE, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the Raymond James 45th Annual Institutional Investors Conference being held in Orlando, Florida, March 3-6, 2024. ICU Medical's presentation will be on Monday, March 4, 2024 at 4:30 a.m. PT (7:30 a.m. ET). Company management will also be participating in one-on-one meetings on Monday, March 4, 2024.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ICUI.